优化基于组织病理学生长模式的结节性淋巴细胞为主型霍奇金淋巴瘤风险分组:德国霍奇金研究组分析
该研究纳入583例在德国霍奇金研究组(GHSG)试验中接受一线治疗的结节性淋巴细胞为主型霍奇金淋巴瘤(NLPHL)患者,比较不同组织病理学生长模式(GP)分组方式对预后分层的区分能力。结果显示GP ABCF vs DE分组可显著区分无进展生存(PFS)和总生存(OS),GP DE组结局更差;而GP AB vs CDEF和GP ABC vs DEF分组未见PFS和OS差异。
要点
- GP ABCF vs DE分组可区分NLPHL的PFS和OS,GP DE组结局更差。
- GP AB vs CDEF和GP ABC vs DEF分组未见PFS和OS差异。
- GP DE组死亡时间更短且死于NLPHL的比例更高。
核心结论
- 将GP分为GP ABCF vs DE可实现基于GP的NLPHL风险分组优化。
研究设计与样本
- 纳入583例在GHSG试验中接受一线治疗的NLPHL患者进行分析。
- 中位年龄39岁;74%为男性;76%为早期Stage,24%为晚期Stage。
主要发现
- 全部患者5年和10年PFS估计值分别为85.9%和76.6%;OS估计值分别为95.8%和94.5%。
- GP ABCF vs DE比较中,GP DE组PFS更差(HR 1.7;95%CI 1.1-2.7),OS更差(HR 2.5;95%CI 1.1-5.7)。
- GP AB vs CDEF和GP ABC vs DEF比较均未观察到PFS和OS差异。
- GP DE组中位死亡时间13个月、死于NLPHL比例66.7%,GP ABCF组分别为31个月和5.6%。
临床怎么用
- 原文结论认为GP ABCF vs DE分组可实现基于GP的NLPHL风险分组优化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Histopathological growth patterns (GP) in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) have previously been divided into GP AB (typical) vs CDEF (variant). However, it is unclear whether this division is optimal. We thus investigated alternative GP grouping approaches (GP ABC vs DEF; GP ABCF vs DE). Overall, 583 NLPHL patients who had first-line treatment within GHSG trials were included in the analysis. Median age was 39 years; 74% of patients were male; 76% presented with early-stage and 24% with advanced-stage disease. The 5-year and 10-year progression-free survival (PFS) estimates for all patients were 85.9% and 76.6%; overall survival (OS) estimates were 95.8% and 94.5%. Significant PFS and OS differences were detected for the comparison GP ABCF vs DE with worse outcomes for the GP DE group (HR: 1.7; 95%-CI: 1.1-2.7; HR: 2.5; 95%-CI: 1.1-5.7). No PFS and OS differences were observed for the comparisons GP AB vs CDEF and GP ABC vs DEF. Median time to death was shorter and death more often due to NLPHL in the GP DE (13 months; 66.7%) than in the GP ABCF (31 months; 5.6%) group. Hence, the division of GP into GP ABCF vs DE allows an optimized GP-based risk group discrimination in NLPHL.
引用
- Eichenauer DA, Basaran A, Bühnen I, et al. Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Leukemia. 2025. PMID: 40360880. doi:10.1038/s41375-025-02641-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。